LP
TERN

LMR Partners’s Terns Pharmaceuticals TERN Stock Holding History

LMR Partners’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.1M Buy
+400,000
New +$16.4M 0.05% 204
2025
Q1 		– Sell
-20,000
Closed -$111K – 1636
2024
Q4 		$111K Hold
20,000
– – ﹤0.01% 990
2024
Q3 		$167K Buy
+20,000
New +$165K ﹤0.01% 1012
2023
Q2 		– Sell
-15,849
Closed -$188K – 1109
2023
Q1 		$188K Buy
+15,849
New +$151K ﹤0.01% 866

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

LMR Partners's TERN Position: Q1 2026 in Review

LMR Partners opened a new position in Terns Pharmaceuticals (TERN) in Q1 2026: 400,000 shares worth $21.1M. The stake represents 0.05% of the portfolio and ranks #204 among its holdings. This is a return to the name: LMR Partners previously reported a position in TERN as recently as Q4 2024.

LMR Partners first reported a position in TERN in Q1 2023 and has held it in 4 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • LMR Partners held 400,000 shares of Terns Pharmaceuticals worth $21.1M as of Q1 2026.
  • Terns Pharmaceuticals was a new LMR Partners position in Q1 2026.
  • Terns Pharmaceuticals made up 0.05% of LMR Partners's portfolio in Q1 2026, its #204 holding.
  • LMR Partners first reported a position in Terns Pharmaceuticals in Q1 2023 and has held it in 4 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.